Monday, October 5, 2026

Every Enterprise Plans AI Agents, but Only About 45% of Company Data Is Ready for Them

A survey says 100% of enterprises expect to use agentic AI within two years, yet only about 45% of company data is AI-accessible. We set that against Nvidia's checked SEC figures and CB Insights startup interviews. The survey source has a poor verification record, so we flag it.

LM Salvado

October 4, 2026

Every Enterprise Plans AI Agents, but Only About 45% of Company Data Is Ready for Them
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The gap between ambition and plumbing

The headline adoption number is unambiguous: within two years, 100% of surveyed organizations plan to use agentic AI, and 69% expect to use it widely.1 The constraint is data. On average only about 45% of company data is accessible to AI, and in organizations categorized as 'data laggards' that falls to 30% or less.1 Only about half of organizations trust their agents' decisions.1 For practitioners, the bottleneck in this picture is access to trustworthy, structured data rather than model capability.

A caution about the source. The report, MIT Technology Review's "Scaling AI agents with trustworthy data," has a measured reliability record of 0% of 11 checked claims holding up.1 We are not saying the figures are wrong. We are saying nobody has yet confirmed them against an independent source, so read them as a direction of travel and not as settled measurements. The pattern is plausible and consistent with the deal activity below, but the exact percentages should be treated as unverified.

Incumbents are buying governance, not just models

The big-company announcements in the dossier are about control as much as capability. Manulife and Microsoft announced a five-year agreement under which Manulife adopts Microsoft's Frontier Suite, deploys Microsoft Agent 365, and expands Microsoft 365 Copilot to more than 30,000 employees.2 Shamus Weiland called the partnership "a critical enabler of Manulife's continued evolution into a truly AI-driven organization."2 The announcement's own title leads with "Enterprise AI Governance."2

Box's July 21 announcement points the same way. It introduced agent guardrails, third-party agent activity oversight, prompt injection detection, and agent classification-based access policies.3 Nomura Research Institute's Tatsutoshi Murata said the company expects Box "to provide the administrative features needed to safely leverage this new era of AI."4 He also valued Box's multi-vendor support, which lets NRI switch flexibly between AI models.4 The customer concern in both cases is how to let agents touch company content without losing control of it, which is the same trust gap the survey describes.

Both press releases come from NewsEOD, whose measured reliability is 57% of 4,954 checked claims holding up.2 They are company announcements, so they show what the companies want to be seen doing and not how well it works. Siemens and NVIDIA are also reported to be deepening ties, but the dossier gives no detail beyond that.5

Startups are pricing against labor, not software

CB Insights' Enterprise AI interviews show how vertical players size their opportunity. Covecta's Ben Thomas says its market is "tens of thousands of financial institutions globally," and that "we are not just disrupting their software budget but their labor budget as well."6 Covecta deploys what it calls seasoned banker agents for workflows and portfolio activities, serving banks, non-bank lenders, building societies, credit unions and private credit firms in the US and UK.6

Penguin AI makes the same move in healthcare. Glenn Herzberg said the company defines its market as administrative labor spend, not the healthcare IT software budget. He put US healthcare administration at about a trillion dollars a year, about a quarter of total health spend, and said published estimates put around $570 billion of that in work that has no effect on health outcomes.7 Those are the company's claims and estimates it cites, not figures we have checked.

Maisa AI's David Villalon describes a similar target: process automation of core business tasks at regulated industries, where work must be auditable, reproducible and hallucination resistant.8 The requirement that agents be auditable echoes the governance demands from Manulife and Box. It also suggests that vertical agents will be judged on how well their work can be checked, as well as on how much work they do.

Funding and attention are flowing in. Latitude, a payments platform founded by an ex-Stripe crypto team member, raised a $35M Series A on September 10, 2026 for stablecoin-to-local-currency payments.9 CB Insights also published interviews on September 22 and 24 with executives at Veridox, Binary World, Shepherd, Arlo and LARX.10 Those are interviews, not evidence of traction, and the dossier contains no revenue or customer data for any of these startups.

The compute layer: Nvidia's checked numbers

The one area where our evidence is checked against SEC filings is Nvidia, the company behind the NeMo Agent Toolkit, NeMo Guardrails and the Nemotron 3 Super model, according to our entity graph.11 The same graph lists Mount Sinai Health System, the State of Alaska Legislative Affairs Agency and Yum! Brands as Nvidia customers, and AMD as a competitor.11

Nvidia's cost of revenue, which is what it spends to deliver its products, was $16.621 billion in fiscal 2024, $32.639 billion in fiscal 2025 and $62.475 billion in fiscal 2026.12 That is roughly 3.8 times the fiscal 2024 level in two years. For scale, $62.475 billion is only the cost side of one company's income statement, before any profit. Cost of revenue is a volume signal, so it indicates how much hardware and related product is being shipped, but it says nothing on its own about profit.

Earnings per share reads less cleanly: $11.93 in fiscal 2024, $2.94 in fiscal 2025 and $4.90 in fiscal 2026.13 The dossier does not explain the swing, so we do not interpret it. The figures are checked as reported, but the three years should not be compared directly without knowing how the share count changed. Nvidia's year-end cash was $7.28 billion in fiscal 2024, $8.589 billion in fiscal 2025 and $10.605 billion in fiscal 2026.14 The latest quarter in the dossier, Q1 fiscal 2027, shows $13.237 billion, below the $15.234 billion at the end of Q1 fiscal 2026.14 Quarter-to-quarter cash moves for many reasons, and the dossier does not say why.

Chip supply is also being planned well ahead. Alibaba's T-Head Zhenwu V900 AI chip is scheduled for commercial release in Q3 2027.15 A scheduled release is a plan, not a shipment.

What we make of it

Via News's analysis of the data suggests the story is shifting from model capability to data readiness and governance. The evidence for this is the pairing of an unverified survey finding, which says data access is the bottleneck, with two verified-as-announced deals that center on oversight. Startups in finance and healthcare are pricing themselves against the labor they replace. That is a bigger market than software budgets, and a bolder claim to make.

What to watch

  • Whether independent surveys reproduce the 45% AI-accessible-data figure, given that the original source has no verified claims so far.
  • Whether Nvidia's cost of revenue keeps climbing in the quarters after Q1 fiscal 2027, and what drives the fall in quarter-end cash.
  • Whether vertical agent companies such as Covecta, Penguin AI and Maisa publish customer or revenue evidence to back their labor-budget sizing.
  • Whether Manulife's 30,000-employee Copilot expansion produces any reported results.
  • Whether the Zhenwu V900 launches on its Q3 2027 schedule.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· July 21, 2026
    Box Unveils New Controls to Secure AI Agents Operating Across Enterprise Content
  2. [2]News articleCB Insights
    CEO Interview: David Villalon, Maisa
  3. [3]News articleCB Insights
    Executive Interview: Covecta
  4. [4]News articleCB Insights
    Executive Interview: Penguin AI
  5. [5]News articleCB Insights
    Investor Interview: Primary on Casap
  6. [6]News articleYahoo Finance· July 22, 2026
    Manulife Expands Partnership with Microsoft to Accelerate Enterprise AI Governance and Innovation
  7. [7]News articleMIT Technology Review
    Scaling AI agents with trustworthy data
  8. [8]News articleMotley Fool
    C3.ai CEO Thomas Siebel Sells 453,000 Shares for $4.8 Million
  9. [9]News articleCB Insights
    CEO Interview: Arlo
  10. [10]News articleCB Insights
    CEO Interview: Binary World
  11. [11]News articleCB Insights
    CEO Interview: LARX
  12. [12]News articleCB Insights
    CEO Interview: Shepherd
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com